コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ntiretroviral therapy (protease inhibitor or nonnucleoside reverse transcriptase inhibitor).
2 p practical syntheses of quinazolinone-based nonnucleoside reverse transcriptase inhibitors.
3 tiretroviral therapy containing NVP or other nonnucleoside reverse transcriptase inhibitors.
4 yclosporine compared with patients receiving nonnucleoside reverse transcriptase inhibitors.
5 leoside reverse-transcriptase inhibitors and nonnucleoside reverse-transcriptase inhibitors.
6 ce (n = 73): no major mutations (3% vs 51%), nonnucleoside reverse transcriptase inhibitor (94% vs 44
7 performed similarly in the quantification of nonnucleoside reverse transcriptase inhibitor and lamivu
9 also showed increased susceptibility to two nonnucleoside reverse transcriptase inhibitors and the p
10 resistance mutations increased resistance to nonnucleoside reverse transcriptase inhibitors and vice
12 gnant women, whereas genotypic resistance to nonnucleoside reverse-transcriptase inhibitors and prote
13 ucleoside analogues, protease inhibitors, or nonnucleoside reverse-transcriptase inhibitors and the h
15 s, 4 (5%) included mutations associated with nonnucleoside reverse-transcriptase inhibitors, and 3 (3
17 randomized to lopinavir/ritonavir (LPV/r) or nonnucleoside reverse transcriptase inhibitor-based ART
19 % (95% confidence interval [CI], 90%-99.7%); nonnucleoside reverse transcriptase inhibitor-based, 100
20 ems to involve use of a tenofovir-containing nonnucleoside reverse-transcriptase inhibitor-based firs
21 oL [95% CI, 15-62]; P = .001), compared with nonnucleoside reverse-transcriptase inhibitor-based regi
22 with a protease inhibitor (indinavir) and a nonnucleoside reverse transcriptase inhibitor (DMP-266).
23 y is applied to the syntheses of the NNRTIs (nonnucleoside reverse transcriptase inhibitors) DPC 961
24 oderate (5%-15%) levels of resistance to the nonnucleoside reverse transcriptase inhibitor drug class
25 n patients receiving tenofovir prodrugs, the nonnucleoside reverse transcriptase inhibitors efavirenz
26 with the protease inhibitor nelfinavir, the nonnucleoside reverse-transcriptase inhibitor efavirenz,
27 lutegravir, elvitegravir, or raltegravir), a nonnucleoside reverse transcriptase inhibitor (efavirenz
28 emtricitabine or abacavir/lamivudine) plus a nonnucleoside reverse transcriptase inhibitor (efavirenz
29 Resistance to the nonnucleoside reverse transcriptase inhibitors etravirin
30 patients received combination therapy with a nonnucleoside reverse-transcriptase inhibitor for at lea
31 otease inhibitors, and 25.6 percent received nonnucleoside reverse-transcriptase inhibitors for a med
32 an ART regimen that combined nucleoside and nonnucleoside reverse-transcriptase inhibitors (hereafte
33 hildren receiving nucleoside with or without nonnucleoside reverse-transcriptase inhibitors, higher i
34 ed in 3 (2%) of 141 subjects, including to a nonnucleoside reverse transcriptase inhibitor in 1 patie
35 ide reverse transcriptase inhibitors in 62%, nonnucleoside reverse transcriptase inhibitors in 57%, p
36 hibitors was found in 10 individuals, to any nonnucleoside reverse transcriptase inhibitors in 6 subj
38 The nonnucleoside reverse transcriptase inhibitor nevirapine
39 The nonnucleoside reverse transcriptase inhibitor nevirapine
40 The HIV PIs lopinavir and saquinavir, the nonnucleoside reverse-transcriptase inhibitor nevirapine
42 ently demonstrated that a formulation of the nonnucleoside reverse transcriptase inhibitor (NNRTI) MI
43 hibitor (NRTI) mutations (4.5%), followed by nonnucleoside reverse transcriptase inhibitor (NNRTI) mu
45 human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase inhibitor (NNRTI) re
46 used to explore risk factors associated with nonnucleoside reverse transcriptase inhibitor (NNRTI) re
48 er-to-child-transmission of HIV-1, transient nonnucleoside reverse transcriptase inhibitor (NNRTI) th
50 ranscriptase complexed with CP-94,707, a new nonnucleoside reverse transcriptase inhibitor (NNRTI), t
51 iving TDF 300 mg every 48 hours as part of a nonnucleoside reverse transcriptase inhibitor (NNRTI)- o
52 users of modern protease inhibitor (PI)- and nonnucleoside reverse transcriptase inhibitor (NNRTI)-ba
53 the risk of virologic failure for first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-ba
56 23.8%) of 21 infants analyzed; 4 (80.0%) had nonnucleoside reverse transcriptase inhibitor (NNRTI)-re
57 evealed that ADAM II acted biologically as a nonnucleoside reverse transcriptase inhibitor (NNRTI).
58 ified a benzophenone template as a potential nonnucleoside reverse transcriptase inhibitor (NNRTI).
59 naive (N = 105) or on a regimen containing a nonnucleoside reverse transcriptase inhibitor (NNRTI; N
60 ate complexes of alkenyldiarylmethane (ADAM) nonnucleoside reverse transcriptase inhibitors (NNRTI) 3
61 ficiency virus type 1 (HIV-1) infection with nonnucleoside reverse transcriptase inhibitors (NNRTI) o
62 M profile 1 [TAM1]) profiles at t0, use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) at
63 became undetectable markedly faster than did nonnucleoside reverse-transcriptase inhibitor (NNRTI) mu
65 p 5230 evaluated patients failing an initial nonnucleoside reverse-transcriptase inhibitor (NNRTI) re
66 was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) re
67 (HIV-1) transmission but may also select for nonnucleoside reverse-transcriptase inhibitor (NNRTI) re
68 iptase inhibitor (NRTI) resistance, 9.8% had nonnucleoside reverse-transcriptase inhibitor (NNRTI) re
70 surveys among patients initiating first-line nonnucleoside reverse-transcriptase inhibitor (NNRTI)-ba
71 ral therapy (ART) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-ba
72 VL were as follows: exposure to nonstandard nonnucleoside reverse-transcriptase inhibitor (NNRTI)-ba
73 ne in renal function than patients receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)-ba
75 etermine the effect of pre-existing minority nonnucleoside reverse-transcriptase inhibitor (NNRTI)-re
78 l 1, 5-diphenylpyrazole (DPP) class of HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs)
80 reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs)
83 Increases in the prevalence of resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs)
88 analog reverse transcriptase inhibitors, and nonnucleoside reverse transcriptase inhibitors (NNRTIs)
91 n clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs),
92 de reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs),
93 5 (P = .003), mainly driven by resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs).
94 pe 1 (HIV-1) particles and susceptibility to nonnucleoside reverse transcriptase inhibitors (NNRTIs).
97 with HIV containing resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs).
98 reverse transcriptase inhibitors [NRTIs] and nonnucleoside reverse transcriptase inhibitors [NNRTIs])
99 4% [P < 0.001] in patients receiving PIs and nonnucleoside reverse transcriptase inhibitors [NNRTIs],
100 to exhibit dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTIs an
103 cell count, and first-line regimens based on nonnucleoside reverse transcriptase inhibitors or integr
104 htly higher for protease inhibitors than for nonnucleoside reverse transcriptase inhibitors or nucleo
105 erse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a riton
106 antiretroviral therapy (ART) with at least 1 nonnucleoside reverse-transcriptase inhibitor or proteas
107 respectively) but not among mothers who used nonnucleoside reverse-transcriptase inhibitor or triple-
108 offer an alternative to regimens containing nonnucleoside reverse-transcriptase inhibitors or protea
109 reverse transcriptase inhibitors (NRTIs) or nonnucleoside reverse transcriptase inhibitors reduced t
110 Among participants with HIV-1 infection, nonnucleoside reverse-transcriptase inhibitor resistance
112 sensitive phenotypic assay is able to detect nonnucleoside reverse transcriptase inhibitor-resistant
114 2.6% (95% confidence interval, 0.07%-13.8%) nonnucleoside reverse-transcriptase inhibitor TDR was de
115 nly used antiretroviral medications, such as nonnucleoside reverse transcriptase inhibitors, the dete
116 f nucleoside reverse-transcriptase inhibitor/nonnucleoside reverse-transcriptase inhibitor treatment
120 ieved in serum; other PIs and nucleoside and nonnucleoside reverse-transcriptase inhibitors were inac
121 ntiretrovirals (e.g., protease inhibitors or nonnucleoside reverse transcriptase inhibitors), which l
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。